BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts

Biohaven Ltd. (BHVN) faces a securities investigation after the FDA placed a partial clinical hold on its epilepsy treatment BHV-7000, causing shares to drop 15% on Sept. 10. Levi & Korsinsky LLP is probing potential securities law violations. The FDA's action is based on insufficient data on a metabolite observed in rodent tests. Biohaven maintains that over 1,200 participants have safely received BHV-7000, and topline results from a pivotal study remain on track for 2026.

Biohaven's epilepsy drug trials paused by FDA due to rodent study findings. New enrollments halted, but current patients continue dosing. Biohaven shares fell over 10% post-announcement. The company expects new animal data soon and maintains the drug has been safe in over 1,200 participants. Top-line results from one study are still expected in 2H 2026.

Biohaven (BHVN) announced an FDA partial clinical hold on new patient enrollment for its BHV-7000 program due to nonclinical rodent testing. The company paused new enrollment pending additional data, but ongoing studies and dosing continue. Biohaven shares fell 14.93% to $12.76 on Thursday, according to Benzinga Pro data.

Biohaven (BHVN) shares fell 10% after the FDA placed a partial hold on its epilepsy drug trial due to concerns about a metabolite found in animal studies. The company expects additional data soon and notes that over 1,200 participants have already received the drug with a favorable safety profile. Biohaven recently licensed its Kv7 platform, including the drug, to SK Biopharmaceuticals for up to $795 million. The hold does not affect the timeline for one of the trials, with results still expecte

Biohaven Ltd. (BHVN) shares dropped 17% after the FDA placed a partial hold on BHV-7000 trials, pausing new patient enrollment. The FDA requested additional studies on a metabolite observed in rodent tests. Over 600 existing patients will continue treatment. Biohaven expects to provide further data soon and maintains that the findings may not be relevant to humans.

Biohaven's stock fell 13% after the FDA paused enrollment in pivotal trials for its epilepsy drug BHV-7000 due to rodent testing concerns. This is the second regulatory setback in a year. The company expects topline data from one trial later this year but may delay another. Biohaven believes the findings may not be relevant to human safety.